Core Viewpoint - The company has noted the approval of a generic version of its patented product Budesonide Enteric-Coated Capsules (Nafacon®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company holds a valid patent (ZL200980127272.5) for Nafacon® in China, which is registered on the national drug patent information platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products within the patent protection scope without the company's permission before the patent expires, or it will constitute patent infringement [1] - The company reserves the right to take legal action against any infringement of the patent rights and commitments made by generic drug applicants [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet significant medical needs, highlighting the importance of a robust patent protection system for the sustainable accessibility of innovative drugs [2] - The improving intellectual property protection environment in China's pharmaceutical industry provides strong support for innovation and healthy industry development [2] - The company aims to continue collaborating with various parties to respect and uphold intellectual property rights, fostering a fair competitive environment for the ongoing development of innovative drugs [2]
云顶新耀(01952)：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态